| アブストラクト | OBJECTIVE: Antipsychotics have conflicting data with respect to obsessive-compulsive disorder/symptoms (OCD/OCS), with some reporting causality and some reporting treatment benefits. This pharmacovigilance study aimed to investigate reporting of OCD/OCS in association with the use of antipsychotics in comparison to one another, as well as treatment failure using data derived from the FDA Adverse Event Reporting System (FAERS). METHODS: Data from January 1st, 2010 to December 31st, 2020 on suspected adverse drug reactions (ADRs) including OCD/OCS was obtained. The information component (IC) was used to determine a disproportionality signal, and reporting odds ratio (ROR) calculations were performed via intra-class analyses to discern differences between the evaluated antipsychotics. RESULTS: A total of 1454 OCD/OCS cases were utilized in IC and ROR calculations and 385,972 suspected ADRs were used as non-cases. A significant disproportionality signal was seen with all second generation antipsychotics. Relative to other antipsychotics, only aripiprazole had a significant ROR of 23.87 (95% CI: 21.01-27.13; p < 0.0001). The ROR for antipsychotic treatment failure in those with OCD/OCS was highest with aripiprazole, and lowest with risperidone and quetiapine. Sensitivity analyses were largely in favor of the primary findings. Our analysis appears to implicate the 5-HT(1A) receptor or an imbalance between this receptor and the D(2) -receptor in antipsychotic treatment-emergent OCD/OCS. CONCLUSIONS: In contrast to prior reports noting clozapine as the antipsychotic most commonly associated with de novo or exacerbated OCD/OCS, this pharmacovigilance study found aripiprazole was most frequently reported for this adverse effect. While these findings from FAERS offer a unique perspective on OCD/OCS with different antipsychotic agents, due to the inherent limitations of pharmacovigilance studies they should ideally be validated through alternative prospective research studies involving direct comparisons of antipsychotic agents. |
|---|
| ジャーナル名 | Acta psychiatrica Scandinavica |
|---|
| Pubmed追加日 | 2023/5/17 |
|---|
| 投稿者 | Burk, Bradley G; DiGiacomo, Tilyn; Polancich, Shea; Pruett, Brandon S; Sivaraman, Soumya; Birur, Badari |
|---|
| 組織名 | Department of Pharmacy, University of Alabama at Birmingham Medical Center,;Birmingham, Alabama, USA.;McWhorter School of Pharmacy, Samford University, Birmingham, Alabama, USA.;Department of Nursing, University of Alabama at Birmingham Medical Center,;School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA.;Department of Psychiatry, University of Alabama at Birmingham Medical Center,;Department of Psychiatry and Behavioral Neurobiology, University of Alabama at;Birmingham Heersink School of Medicine, Birmingham, Alabama, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37194481/ |
|---|
